Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Neuropace, Inc. - Common Stock
(NQ:
NPCE
)
8.285
+0.085 (+1.04%)
Delayed Quote
Updated: 1:14 PM EST, Nov 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Neuropace, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
NPCE Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into NeuroPace (NPCE)
Today 10:15 EST
From
Levi & Korsinsky, LLP
Via
ACCESS Newswire
NEUROPACE, INC. INVESTIGATION: NPCE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights
November 17, 2026
From
Kirby McInerney LLP
Via
Business Wire
Unusual Volume Market Movers for November 16, 2026
↗
November 16, 2026
Via
Chartmill
Today's US Session Top Gainers and Losers: ONFO, AKAN Lead Advances; OPTT, NPCE Fall
↗
November 13, 2026
Via
Chartmill
NeuroPace (NASDAQ:NPCE) Beats Q1 Estimates, Raises Full-Year Revenue Guidance
↗
May 12, 2026
Via
Chartmill
Top US Market Movers: Gainers and Losers in Today's Session
↗
November 13, 2026
Via
Chartmill
Gap Movers for Nov. 13, 2026: Gap-Up and Gap-Down Stocks
↗
November 13, 2026
Via
Chartmill
Premarket Session Market Movers: Small-Cap Gainers and Losers
↗
November 13, 2026
Via
Chartmill
NeuroPace (NPCE) Q3 2026 Earnings Call Transcript
↗
November 13, 2026
Account issues and sales restructuring pressured results, prompting a guidance cut.
Via
The Motley Fool
Topics
Earnings
What NeuroPace (NPCE) Said on Its Q3 Earnings Call
↗
November 12, 2026
NeuroPace (NASDAQ:NPCE) cut its full-year revenue outlook after third-quarter sales fell short of management’s expectations, as disruptions at major treatment centers and changes to its sales...
Via
MarketBeat
Topics
Earnings
NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance
November 12, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026
October 29, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
September 01, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
August 31, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace Q2 Earnings Call Highlights
↗
August 11, 2026
NeuroPace (NASDAQ:NPCE) reported second-quarter revenue growth driven by continued adoption of its RNS System for adult focal epilepsy, while raising its full-year revenue and adjusted EBITDA outlook....
Via
MarketBeat
Topics
Earnings
NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
August 11, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace FDA Bid for Expanded Epilepsy Use Stalls as Agency Seeks More Data
↗
July 28, 2026
NeuroPace (NASDAQ:NPCE) said the U.S. Food and Drug Administration determined that its premarket approval supplement seeking to expand the RNS System indication to patients with medication-resistant...
Via
MarketBeat
These stocks are moving in today's after hours session
↗
July 28, 2026
Via
Chartmill
NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy
July 28, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting
May 29, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
May 29, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace (NPCE) Q1 2026 Earnings Transcript
↗
May 14, 2026
NeuroPace (NPCE) Q1 2026 Earnings Transcript
Via
The Motley Fool
Topics
Artificial Intelligence
NeuroPace Q1 Earnings Call Highlights
↗
May 12, 2026
NeuroPace (NASDAQ:NPCE) raised its 2026 revenue outlook after reporting first-quarter results that management said reflected continued demand for its RNS System and improving commercial execution...
Via
MarketBeat
Topics
Artificial Intelligence
Earnings
NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
May 12, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026
April 29, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026
April 27, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
April 10, 2026
From
NeuroPace, Inc.
Via
Business Wire
NeuroPace to Present at the Leerink Global Healthcare Conference
March 05, 2026
From
NeuroPace, Inc.
Via
Business Wire
Why NeuroPace Stock Was Inching Higher on Wednesday
↗
March 04, 2026
The company finished 2025 with a convincing pair of earnings beats.
Via
The Motley Fool
NeuroPace (NPCE) Q4 2025 Earnings Call Transcript
↗
March 03, 2026
NeuroPace (NPCE) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.